KBH-A42, a histone deacetylase inhibitor, inhibits the growth of doxorubicin-resistant leukemia cells expressing P-glycoprotein

Oncology Reports

Volumn 23, Issue 3, 2010, Pages 801-809

  Kang, Moo Rim ^a   Lee, Kiho ^a   Kang, Jong Soon ^a   Lee, Chang Woo ^a   Lee, Ki Hoon ^a   Kim, Jang Hyun ^a   Yang, Jeong Wook ^a   Kim, Bo Geun ^a   Han, Gyoonhee ^b   Kang, Jong Seong ^c   Park, Song Kyu ^a   Kim, Hwan Mook ^a  

^a Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^b Yonsei University   (South Korea)

^c Chungnam National University   (South Korea)

Author keywords

Apoptosis; Caspase; Cell cycle arrest; Histone deacetylase inhibitor; p21 WAF1

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR 1; DOXORUBICIN; GLYCOPROTEIN P; HISTONE DEACETYLASE INHIBITOR; KBH A42; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL DEATH; CELL GROWTH; CELL STRAIN K 562; DOWN REGULATION; DRUG ACTIVITY; DRUG MECHANISM; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

APOPTOSIS; CASPASES; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; G0 PHASE; G1 PHASE; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; K562 CELLS; P-GLYCOPROTEIN; PIPERIDONES;

EID: 77349122761     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00000701     Document Type: Article

References (24)

1. Tan B, Piwnica-Worms D and Ratner L: Multidrug resistance transporters and modulation. Curr Opin Oncol 12: 450-458, 2000.
2. Gottesman MM and Pastan I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62: 385-427, 1993.
3. Nielsen D and Skovsgaard T: P-glycoprotein as multidrug transporter: a critical review of current multidrug resistant cell lines. Biochim Biophys Acta 1139: 169-183, 1992.
4. Grogan TM, Spier CM, Salmon SE, Matzner M, Rybski J, Weinstein RS, Scheper RJ and Dalton WS: P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood 81: 490-495, 1993.
5. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I and Gottesman MM: Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39: 361-398, 1999.
6. Carew JS, Giles FJ and Nawrocki ST: Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett 269: 7-17, 2008.
7. Han JW, Ahn SH, Park SH, Wang SY, Bae GU, Seo DW, Kwon HK, Hong S, Lee HY, Lee YW and Lee HW: Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin. Cancer Res 60: 6068-6074, 2000.
8. Kwon SH, Ahn SH, Kim YK, Bae GU, Yoon JW, Hong S, Lee HY, Lee YW, Lee HW and Han JW: Apicidin, a histone deacetylase inhibitor, induces apoptosis and Fas/Fas ligand expression in human acute promyelocytic leukemia cells. J Biol Chem 277: 2073-2080, 2002.
9. Ruefli AA, Bernhard D, Tainton KM, Kofler R, Smyth MJ and Johnstone RW: Suberoylanilide hydroxamic acid (SAHA) overcomes multidrug resistance and induces cell death in P-glycoprotein-expressing cells. Int J Cancer 99: 292-298, 2002.
10. Castro-Galache MD, Ferragut JA, Barbera VM, Martin-Orozco E, Gonzalez-Ros JM, Garcia-Morales P and Saceda M: Susceptibility of multidrug resistance tumor cells to apoptosis induction by histone deacetylase inhibitors. Int J Cancer 104: 579-586, 2003.
11. Huang L, Sowa Y, Sakai T and Pardee AB: Activation of the p21WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites. Oncogene 19: 5712-5719, 2000.
12. Richon VM, Sandhoff TW, Rifkind RA and Marks PA: Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 97: 10014-10019, 2000.
13. Gui CY, Ngo L, Xu WS, Richon VM and Marks PA: Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci USA 101: 1241-1246, 2004.
14. Johnstone RW, Ruefli AA and Lowe SW: Apoptosis: a link between cancer genetics and chemotherapy. Cell 108: 153-164, 2002.
15. Doi S, Soda H, Oka M, Tsurutani J, Kitazaki T, Nakamura Y, Fukuda M, Yamada Y, Kamihira S and Kohno S: The histone deacetylase inhibitor FR901228 induces caspase-dependent apoptosis via the mitochondrial pathway in small cell lung cancer cells. Mol Cancer Ther 3: 1397-1402, 2004.
16. Kang MR, Kang JS, Han SB, Kim JH, Kim DM, Lee K, Lee CW, Lee KH, Lee CH, Han G, Kim HM and Park SK: A novel delta-lactam-based histone deacetylase inhibitor, KBH-A42, induces cell cycle arrest and apoptosis in colon cancer cells. Biochem Pharmacol 78: 486-494, 2009.
17. Shiraki N, Hamada A, Yasuda K, Fujii J, Arimori K and Nakano M: Inhibitory effect of human immunodeficiency virus protease inhibitors on multidrug resistance transporter Pglycoproteins. Biol Pharm Bull 23: 1528-1531, 2000.
18. Krishan A: Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining. J Cell Biol 66: 188-193, 1975.
19. Smyth MJ, Krasovskis E, Sutton VR and Johnstone RW: The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. Proc Natl Acad Sci USA 95: 7024-7029, 1998.
20. Simon SM and Schindler M: Cell biological mechanisms of multidrug resistance in tumors. Proc Natl Acad Sci USA 91: 3497-3504, 1994.
21. Johnstone RW, Cretney E and Smyth MJ: P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood 93: 1075-1085, 1999.
22. Ruefli AA, Ausserlechner MJ, Bernhard D, Sutton VR, Tainton KM, Kofler R, Smyth MJ and Johnstone RW: The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci USA 98: 10833-10838, 2001.
23. Jin S and Scotto KW: Transcriptional regulation of the MDR1 gene by histone acetyltransferase and deacetylase is mediated by NF-Y. Mol Cell Biol 18: 4377-4384, 1998.
24. Sakajiri S, Kumagai T, Kawamata N, Saitoh T, Said JW and Koeffler HP: Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. Exp Hematol 33: 53-61, 2005.